Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective - CRLC Val d'Aurelle - Paul Lamarque Accéder directement au contenu
Article Dans Une Revue Vaccines Année : 2020

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective

Résumé

Immune checkpoint inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and their apparently random effect in terms of efficacy and toxicity. This marked pharmacodynamics variability in patients calls for reconsidering to what extent approved dosing used in clinical practice are optimal or whether they should require efforts for customization in outlier patients. To better understand whether or not dosing could be an actionable item in oncology, in this review, preclinical and clinical development of immune checkpoint inhibitors are described, particularly from the angle of dose finding studies. Other issues in connection with dosing issues are developed, such as the flat dosing alternative, the putative role therapeutic drug monitoring could play, the rise of combinatorial strategies, and pharmaco-economic aspects.
Fichier principal
Vignette du fichier
vaccines-08-00632.pdf (319.32 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03280614 , version 1 (07-07-2021)

Licence

Paternité

Identifiants

Citer

Félicien Le Louedec, Fanny Leenhardt, Clémence Marin, Étienne Chatelut, Alexandre Evrard, et al.. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines, 2020, 8 (4), pp.632. ⟨10.3390/vaccines8040632⟩. ⟨hal-03280614⟩
98 Consultations
158 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More